Biologic therapies target specific, dysregulated immune pathways in each pathology, including interleukin 4 receptor (IL4Rα) or Janus kinase 1 (JAK1) inhibitors in atopic dermatitis, interleukin 17 (IL-17) or 23 (IL-23) antagonists in psoriasis, and interleukin 4 (IL-4) and 13 (IL-13) signaling blockers in lichen sclerosus [3,4], representing significant advances in their treatment. This evidence concerns the gene IL4 and lichen sclerosus et atrophicus.